Hisamitsu Pharmaceutical
As of the edition of 20 October 2026, Hisamitsu Pharmaceutical runs 9 drugs, 8 of them marketed; it is on route A at 0 targets and on route B at 8 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Went quiet | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fentanyl | none listed | 6 |
| Estradiol | Ends 2032 (patent) | 6 |
| Diclofenac | none listed | 7 |
| Ketoprofen | none listed | 5 |
| Oxybutynin | none listed | 3 |
| Asenapine | Ended 2026 (patent) | 3 |
| Ropinirole | none listed | 3 |
| Emedastine | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 8 targets.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where Hisamitsu Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 1 trials led
- Skin and connective tissue: 1 trials led